85.7  -0.34 (-0.4%)		10-19 15:24
Open: 86.105 High: 86.6094 Volume: 1,444,259		Pre. Close: 86.04 Low: 85.43 Market Cap: 32,340(M)

Short term
Mid term
Targets	6-month :	102.21	1-year :	105.57
Resists	First :	87.51	Second :	90.38
Pivot price	85.45
Supports	First :	82.86	Second :	68.93
MAs	MA(5) :	85.64	MA(20) :	85.99
	MA(100) :	81.02	MA(250) :	72.07
MACD	MACD :	-0.3	Signal :	-0.4
%K %D	K(14,3) :	67	D(3) :	55.7
RSI	RSI(14): 50
52-week	High :	92.58	Low :	54.11

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DXCM ] has closed below upper band by 39.8%. Bollinger Bands are 55.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	88.98 - 89.42	89.42 - 89.84
Low:	84.62 - 85.16	85.16 - 85.69
Close:	85.05 - 85.9	85.9 - 86.73

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Sat, 17 Oct 2026
DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha

Thu, 15 Oct 2026
A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 - GuruFocus

Thu, 15 Oct 2026
DexCom (NasdaqGS:DXCM) Stock Forecast & Analyst Predictions - Simply Wall Street

Wed, 14 Oct 2026
A glucose monitor added about five hours a day in target blood sugar range for people with type 2 diabetes - Stock Titan

Tue, 13 Oct 2026
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - TradingView

Tue, 13 Oct 2026
DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation - ChartMill

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	377 (M)
Shares Float	376 (M)
Held by Insiders	0.2 (%)
Held by Institutions	106.6 (%)
Shares Short	14,020 (K)
Shares Short P.Month	17,630 (K)

EPS	2.51
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.94
Profit Margin	20.1 %
Operating Margin	24.3 %
Return on Assets (ttm)	10.3 %
Return on Equity (ttm)	38.4 %
Qtrly Rev. Growth	13.1 %
Gross Profit (p.s.)	8.21
Sales Per Share	13.17
EBITDA (p.s.)	3.7
Qtrly Earnings Growth	43.5 %
Operating Cash Flow	1,750 (M)
Levered Free Cash Flow	1,020 (M)

PE Ratio	34.11
PEG Ratio	2.1
Price to Book value	12.36
Price to Sales	6.52
Price to Cash Flow	18.53

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.